CytoReason vs Emendo Biotherapeutics
CytoReason vs Emendo Biotherapeutics, compared side by side on 20 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: CytoReason is on 68/100 and Emendo Biotherapeutics on 59/100.
Where each one leads
CytoReason
- our overall score: 68/100 against 59/100
- domain rating: 40/100 against 20/100
- headcount: 116 against 41
- headcount growth: +13.7% against -16.1%
- funding raised: $128M against $61.0M
- LinkedIn following: 12,830 against 5,333
Emendo Biotherapeutics
- agent readiness: 40/100 against 21/100
At a glance
| Measure | CytoReason | Emendo Biotherapeutics |
|---|---|---|
| What it is | Develops a computational model of the human body for drug discovery and development. | Developing genetic medicines and cell therapies for severe diseases using proprietary CRISPR OMNI technology. |
| Category | Healthcare, Drug Discovery, Clinical Development, Biomarkers | Healthcare, Genome Editing, CRISPR, Biotech |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | Platform |
| Founded | 2016 | 2015 |
| Headquarters | Tel Aviv, Israel | Tel Aviv, Israel |
| Status | Active | Active |
Size, funding and growth
| Measure | CytoReason | Emendo Biotherapeutics |
|---|---|---|
| Employees | 116 | 41 |
| Headcount growthLast 12 months | +13.7% | -16.1% |
| Total funding | $128M | $61.0M |
| Latest round | Series B | Series B |
| LinkedIn followers | 12,830 | 5,333 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | CytoReason | Emendo Biotherapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 68/100 | 59/100 |
| Traction | 60/100 | 55/100 |
| Team | 70/100 | 40/100 |
| Search visibility | 30/100 | 44/100 |
| Quality | 78/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (21/100) | D (40/100) |
| Domain ratingLink authority, 0-100 | 40/100 | 20/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | CytoReason | Emendo Biotherapeutics |
|---|---|---|
| Hosting | Not detected | Google Cloud |
| CMS | Not detected | WordPress |
| Frameworks | Not detected | Bootstrap |
| Analytics | Segment | Google Tag Manager |
CytoReason vs Emendo Biotherapeutics: common questions
Which is better, CytoReason or Emendo Biotherapeutics?
On our 0-100 score CytoReason rates higher (68/100 against 59/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 20 data points above: read the rows that match what you are buying for.
How do CytoReason and Emendo Biotherapeutics compare on the numbers?
CytoReason leads on our overall score (68/100 against 59/100), domain rating (40/100 against 20/100), headcount (116 against 41), headcount growth (+13.7% against -16.1%), funding raised ($128M against $61.0M), LinkedIn following (12,830 against 5,333). Emendo Biotherapeutics leads on agent readiness (40/100 against 21/100).
Read the full CytoReason review and pricing or the Emendo Biotherapeutics review and pricing. You can also browse other CytoReason alternatives we track.